From the databaseWhat the row says.
Every entry follows the same shape: what is happening, the mechanism, and the recommendation.
Scope
Supplement × Supplement
Last verified
June 4, 2026
CautionEmerging evidence
What is happening. Both hesperetin and berberine inhibit intestinal and hepatic CYP3A4 and modulate efflux transporters, which could alter the metabolism of co-administered CYP3A4 substrates.
Mechanism. Hesperetin is a known inhibitor of CYP3A4 and P-glycoprotein; berberine likewise inhibits CYP3A4 and P-gp. Combined enzyme/transporter inhibition can raise plasma levels of certain drugs metabolized by these pathways.
Recommendation. The combination itself is generally tolerated, but exercise caution if also taking narrow-therapeutic-index CYP3A4 substrate medications and consult a clinician or pharmacist.
Stack Score
How it moves the number.
Effect on the composite score
If both Berberine and Hesperidin are in the same stack, this pair applies −5 to your Stack Score (per scored caution row).
The full algorithm, the clamping rules, and four worked stacks are at /methodology/stack-score.
SourcesSources, by evidence tier.
Every claim on this page is cited. PMIDs link straight to PubMed.
Reference material
1- 1Guo Y, et al. Repeated administration of berberine inhibits cytochromes P450 in humans. European Journal of Clinical Pharmacology. 2012.Needs sourceNo link